Option Care Health, Inc. to Post Q3 2024 Earnings of $0.31 Per Share, William Blair Forecasts (NASDAQ:OPCH)

Option Care Health, Inc. (NASDAQ:OPCH) – Equities researchers at William Blair dropped their Q3 2024 EPS estimates for Option Care Health in a note issued to investors on Wednesday, April 24th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of $0.31 for the quarter, down from their previous estimate of $0.32. The consensus estimate for Option Care Health’s current full-year earnings is $1.17 per share. William Blair also issued estimates for Option Care Health’s Q4 2024 earnings at $0.35 EPS.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The firm had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.10 billion. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The company’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.21 earnings per share.

Several other equities analysts also recently commented on the company. Jefferies Financial Group increased their price target on Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a report on Monday, March 4th. Barrington Research reiterated an “outperform” rating and set a $38.00 price target on shares of Option Care Health in a report on Wednesday.

Option Care Health Trading Up 1.1 %

Shares of OPCH stock opened at $29.61 on Friday. Option Care Health has a 12 month low of $24.23 and a 12 month high of $35.74. The company has a quick ratio of 1.33, a current ratio of 1.77 and a debt-to-equity ratio of 0.74. The business’s 50 day moving average is $31.96 and its two-hundred day moving average is $31.48. The company has a market cap of $5.15 billion, a PE ratio of 19.48, a price-to-earnings-growth ratio of 1.65 and a beta of 1.22.

Insider Transactions at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. acquired 35,000 shares of the stock in a transaction dated Monday, February 26th. The shares were acquired at an average price of $31.55 per share, for a total transaction of $1,104,250.00. Following the completion of the purchase, the director now owns 269,528 shares in the company, valued at approximately $8,503,608.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Option Care Health

A number of institutional investors have recently bought and sold shares of the business. Park Place Capital Corp boosted its stake in Option Care Health by 48.4% during the first quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock worth $38,000 after buying an additional 372 shares in the last quarter. Parallel Advisors LLC boosted its stake in Option Care Health by 130.2% during the fourth quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock worth $28,000 after buying an additional 478 shares in the last quarter. Securian Asset Management Inc. boosted its stake in Option Care Health by 3.4% during the third quarter. Securian Asset Management Inc. now owns 15,235 shares of the company’s stock worth $493,000 after buying an additional 503 shares in the last quarter. Sheets Smith Wealth Management boosted its stake in Option Care Health by 1.6% during the third quarter. Sheets Smith Wealth Management now owns 32,542 shares of the company’s stock worth $1,053,000 after buying an additional 510 shares in the last quarter. Finally, Principal Securities Inc. acquired a new stake in Option Care Health during the fourth quarter worth $27,000. Institutional investors and hedge funds own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.